Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang.

Slides:

Advertisements

Similar presentations

The prognostic importance of the number of involved lymph nodes in esophageal cancer: Implications for revisions of the American Joint Committee on Cancer.

Advertisements

Stephen R. Broderick, MD, MPHS

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the.

Do tumor location and grade affect survival in pT2N0M0 esophageal squamous cell carcinoma? Dongrong Situ, MD, Junye Wang, MD, PhD, Peng Lin, MD, PhD,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Endoscopic ultrasound is inadequate to determine which T1/T2 esophageal tumors are candidates for endoluminal therapies Edward J. Bergeron, MD, Jules.

Survival of patients with distal esophageal and gastric cardia tumors: A population- based analysis of gastroesophageal junction carcinomas Bryan A. Whitson,

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD

Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small.

Esophageal submucosa: The watershed for esophageal cancer

A novel biomarker for the detection of esophageal adenocarcinoma

Prognostic Value of Different Lymph Node Staging Methods in Esophageal Squamous Cell Carcinoma After Esophagectomy San-Gang Wu, MD, Feng-Yan Li, MD,

Outcomes, quality of life, and survival after esophagectomy for squamous cell carcinoma: A propensity score–matched comparison of operative approaches

Intrinsic cardiac stem cells are essential for regeneration

Tumors of the esophagogastric junction

Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single- institution experience Bin Li, MD, Haiquan Chen, MD, Jiaqing Xiang,

Lobe-specific extent of systematic lymph node dissection for non–small cell lung carcinomas according to a retrospective study of metastasis and prognosis

The prognostic importance of the number of involved lymph nodes in esophageal cancer: Implications for revisions of the American Joint Committee on Cancer.

Multilevel data analysis: What? Why? How?

The influence of preoperative weight loss on the postoperative course after esophageal cancer resection Maartje K. van der Schaaf, MD, Hugo W. Tilanus,

New treatment approaches create new disease processes: A short guide on how to reduce unexpected events to a minimum Martin Czerny, MD, MBA The Journal.

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Propensity score–matched analysis of adjuvant chemotherapy for stage I non–small cell lung cancer Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD,

The lord of the rings Antonio Miceli, MD, PhD

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Radical Lymph Node Dissection in Primary Esophagectomy for Esophageal Squamous Cell Carcinoma Chen-Sung Lin, MD, PhD, Chih-Tao Cheng, MD, DrPH, Chao-Yu.

Gastric conduit revision after esophagectomy: The raising of Lazarus

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

Supraclavicular node metastasis from thoracic esophageal carcinoma: A surgical series from a Japanese multi-institutional nationwide registry of esophageal.

Lung adenocarcinoma: Are skip N2 metastases different from non-skip?

Yang Zhang, MD, Haiquan Chen, MD, PhD

Reduced membranous β-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus Po-Kuei.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Explore the Radiotherapeutic Clinical Target Volume Delineation for Thoracic Esophageal Squamous Cell Carcinoma from the Pattern of Lymphatic Metastases

It's not “just a shunt” but sometimes it should be…

Fixing the supply problem

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease Steven M Keller, MD, Mark G Vangel, PhD, Henry Wagner,

Confusion still exists regarding postoperative delirium and its etiology after esophagectomy Robert B. Cameron, MD The Journal of Thoracic and Cardiovascular.

Stephen R. Broderick, MD, MPHS

Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: Data from the Surveillance Epidemiology.

Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis Alessandro Marra, MD, PhD, Ludger Hillejan, MD,

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

Niv Ad, MD, Lawrence M. Wei, MD

Surgical Treatment for Limited-Stage Primary Small Cell Cancer of the Esophagus Dongrong Situ, MD, Yongbin Lin, MD, PhD, Hao Long, MD, PhD, Lanjun Zhang,

Manuel J. Antunes, MD, PhD, DSc

Pathologic complete response after esophagectomy following neoadjuvant chemoradiation therapy for esophageal carcinoma: A cure sometimes? Shawn S. Groth,

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Carcinoma of the esophagus: Prognostic significance of histologic type

Prognosis and “granularity”: Building on staging foundations?

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Apparently, size matters…in congenital heart disease and brain injury

The continuing challenge of congenital heart disease in China

“The more things change…”: The challenges ahead

Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: What the surgeon needs to know Harold L. Lazar,

Aritoshi Hattori, MD, Kenji Suzuki, MD

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Who should decide margin length in pulmonary excision of lung cancer?

Results of interventional bronchoscopy in the management of postoperative tracheobronchial stenosis Byeong-Ho Jeong, MD, Sang-Won Um, MD, PhD, Gee Young.

Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma Wei-Wei Chen, MD, Feng Wang, MD, PhD, ShaoBin Chen, MD, Luhua Wang,

Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal.

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

Factors predictive of prognosis after esophagectomy for squamous cell cancer Houhuai Li, MD, PhD, Qingzhen Zhang, Lin Xu, MD, Yijiang Chen, Yongxiang Wei, Guoren Zhou, MS The Journal of Thoracic and Cardiovascular Surgery Volume 137, Issue 1, Pages 55-59 (January 2009) DOI: 10.1016/j.jtcvs.2008.05.024 Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Cumulative disease-specific survival curves in terms of tumor pTNM stage. Median survival time for patients with stage 0 (n = 30), stage I (n = 78), stage IIa (n = 111), stage IIb (n = 165), stage III (n = 185), stage IV (n = 36) were 130.0, 130.0, 112.4, 60.8, 49.7, and 26.2 months, respectively (log–rank test, P < .001). The Journal of Thoracic and Cardiovascular Surgery 2009 137, 55-59DOI: (10.1016/j.jtcvs.2008.05.024) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Cumulative disease-specific survival curves in terms of tumor location. Median survival time for patients with upper thoracic cancer (n = 175), middle thoracic esophageal cancer (n = 227), and lower thoracic esophageal cancer (n = 203) were 45.9, 82.2, and 93.8 months, respectively (log–rank test, P < .001). The Journal of Thoracic and Cardiovascular Surgery 2009 137, 55-59DOI: (10.1016/j.jtcvs.2008.05.024) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Cumulative disease-specific survival curves in terms of histologic differentiation of tumor. Median survival time for patients with well (n = 164), moderate (n = 159), poor (n = 189), and undifferentiated (n = 93) were 111.6, 86.7, 54.0, and 43.1 months, respectively (log–rank test; P < .001). The Journal of Thoracic and Cardiovascular Surgery 2009 137, 55-59DOI: (10.1016/j.jtcvs.2008.05.024) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 4 Cumulative disease-specific survival curves in terms of vaso-invasive growth of tumor. Median survival time for patients with negative (n = 358) and positive (n = 247) were 84.6 and 61.3 months, respectively (log-rank test; P < .01). The Journal of Thoracic and Cardiovascular Surgery 2009 137, 55-59DOI: (10.1016/j.jtcvs.2008.05.024) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 5 Cumulative disease-specific survival curves in terms of number of lymph node (LN) metastases (log–rank test; P < .001). The Journal of Thoracic and Cardiovascular Surgery 2009 137, 55-59DOI: (10.1016/j.jtcvs.2008.05.024) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions

Figure 6 Cumulative disease-specific survival curves in terms of postoperative adjuvant radiochemotherapies for the patients with SCC of the thoracic esophagus (n = 579). The 1-, 3-, 5- and 10-year disease-specific survivals for the unnecessary postoperative radiochemotherapy patients (n = 104) were 99%, 96%, 88%, and 63%; for the completed postoperative radiochemotherapy patients (n = 449) were 95%, 72%, 49%, and 17%; and for the incompleted patients (n = 26) were 77%, 56%, 20%, and 0; respectively (log–rank [Mantel–Cox]; P < .001). The Journal of Thoracic and Cardiovascular Surgery 2009 137, 55-59DOI: (10.1016/j.jtcvs.2008.05.024) Copyright © 2009 The American Association for Thoracic Surgery Terms and Conditions